Terns Pharmaceuticals Announces Global Phase 1 Clinical Trial Design Of TERN-701 For The Treatment Of Chronic Myeloid Leukemia
Portfolio Pulse from Benzinga Newsdesk
Terns Pharmaceuticals has announced the design of a global Phase 1 clinical trial for TERN-701, a treatment for chronic myeloid leukemia. The U.S. Food and Drug Administration has cleared the Investigational New Drug application. The design is based on insights from an ongoing Phase 1 trial in China. Patient screening is expected to start in December 2023, with initial data expected in the second half of 2024.
October 16, 2023 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Terns Pharmaceuticals is advancing with its TERN-701 treatment for chronic myeloid leukemia, with a global Phase 1 trial design announced and IND application cleared by the FDA. Initial results are expected in H2 2024.
The announcement of a global Phase 1 trial and the clearance of the IND application by the FDA are positive developments for Terns Pharmaceuticals. These developments indicate progress in the company's pipeline, which could potentially lead to future revenue if the drug is successful. However, the impact on the stock price in the short term may be limited as the initial data from the trial is not expected until the second half of 2024.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100